

Robert E Reiter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6205812/publications.pdf>

Version: 2024-02-01

172
papers

12,044
citations

29994

54
h-index

30010

103
g-index

174
all docs

174
docs citations

174
times ranked

12699
citing authors

#	ARTICLE	IF	CITATIONS
1	Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 207-209.	2.0	8
2	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 544-552.	2.6	16
3	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. <i>European Urology Oncology</i> , 2022, 5, 100-103.	2.6	18
4	The utility of prostate MRI within active surveillance: description of the evidence. <i>World Journal of Urology</i> , 2022, 40, 71-77.	1.2	6
5	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
6	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	5.1	68
7	Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1497-1499.	0.8	2
8	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€‘data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	0.9	19
9	Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena. <i>Journal of Hematology and Oncology</i> , 2022, 15, 48.	6.9	6
10	Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial. <i>Journal of Urology</i> , 2022, 208, 618-625.	0.2	8
11	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	0.9	140
12	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 135-139.	2.0	11
13	High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1505-1515.	3.2	36
14	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
15	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	2.6	3
16	Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. <i>Journal of Urology</i> , 2021, 205, 444-451.	0.2	30
17	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
18	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	2.3	299

#	ARTICLE	IF	CITATIONS
19	The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 258-266.	1.6	19
20	Caught Between a Rock and a Hard Place. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 846-847.	0.4	0
21	Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI. <i>Prostate</i> , 2021, 81, 521-529.	1.2	1
22	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
23	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021, 29, 2335-2349.	3.7	51
24	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	8
25	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
26	Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. <i>Diagnostics</i> , 2021, 11, 1785.	1.3	13
27	Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 595-603.	0.2	19
28	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	3.4	138
29	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	3.4	21
30	MRI-guided Biopsy in Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002343.	0.2	2
31	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
32	[⁸⁹ Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. <i>Molecular Imaging and Biology</i> , 2020, 22, 367-376.	1.3	6
33	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	0.9	18
34	Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2. <i>Abdominal Radiology</i> , 2020, 45, 2225-2234.	1.0	17
35	Efficacy of a preprostatectomy multi-modal penile rehabilitation regimen on recovery of postoperative erectile function. <i>International Journal of Impotence Research</i> , 2020, 32, 323-328.	1.0	17
36	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37

#	ARTICLE	IF	CITATIONS
37	Focal Therapy Should Not Be Considered for Men with Gleason Grade Group 3-5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 203-204.	1.6	2
38	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	2.0	6
39	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
40	Evaluation of [¹³¹ I]- and [¹⁷⁷ Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2020, 22, 1380-1391.	1.3	10
41	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	3.2	10
42	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
43	Impact of ⁶⁸ Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	2.8	74
44	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
45	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
46	Prostate Microstructure in Prostate Cancer Using 3-T MRI with Diffusion-Relaxation Correlation Spectrum Imaging: Validation with Whole-Mount Digital Histopathology. <i>Radiology</i> , 2020, 296, 348-355.	3.6	35
47	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 930-935.	0.4	12
48	Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. <i>American Journal of Roentgenology</i> , 2020, 214, 1101-1111.	1.0	17
49	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
50	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	2.8	94
51	The Role of Opioids and Their Receptors in Urological Malignancy: A Review. <i>Journal of Urology</i> , 2020, 204, 1150-1159.	0.2	14
52	Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. <i>Canadian Journal of Urology</i> , 2020, 27, 10352-10362.	0.0	1
53	A system using patient-specific 3D-printed molds to spatially align in vivo MRI with ex vivo MRI and whole-mount histopathology for prostate cancer research. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 270-279.	1.9	22
54	Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI. <i>American Journal of Roentgenology</i> , 2019, 213, W134-W142.	1.0	28

#	ARTICLE	IF	CITATIONS
55	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
56	Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. <i>BJU International</i> , 2019, 124, 275-281.	1.3	14
57	Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. <i>European Urology</i> , 2019, 76, 18-23.	0.9	50
58	The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 321-330.	1.8	33
59	Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. <i>American Journal of Roentgenology</i> , 2019, 212, W122-W131.	1.0	8
60	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. <i>Cancer</i> , 2019, 125, 2955-2964.	2.0	21
61	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
62	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	0.9	104
63	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. <i>BMC Cancer</i> , 2019, 19, 291.	1.1	17
64	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	2.0	66
65	Automatic Prostate Zonal Segmentation Using Fully Convolutional Network With Feature Pyramid Attention. <i>IEEE Access</i> , 2019, 7, 163626-163632.	2.6	71
66	Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e353-e356.	0.7	5
67	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	3.4	27
68	Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial. <i>European Urology</i> , 2019, 75, 591-592.	0.9	0
69	Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. <i>Clinical Cancer Research</i> , 2019, 25, 188-200.	3.2	23
70	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e53-e55.	0.9	8
71	Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2019, 75, 712-720.	0.9	187
72	PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. <i>Journal of Urology</i> , 2019, 201, 91-97.	0.2	16

#	ARTICLE	IF	CITATIONS
73	Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS ^{v2} Category and Staging with Whole Mount Histopathology Correlation. <i>Journal of Urology</i> , 2019, 201, 496-502.	0.2	21
74	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	3.8	252
75	Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. <i>Abdominal Radiology</i> , 2018, 43, 2487-2496.	1.0	2
76	Potential Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	2.8	81
77	Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. <i>Journal of Urology</i> , 2018, 199, 1218-1223.	0.2	17
78	3T multiparametric MR imaging, PIRADS ^{v2} -based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard. <i>Abdominal Radiology</i> , 2018, 43, 3117-3124.	1.0	13
79	Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti- ⁶⁸ Prostate Stem Cell Antigen Cys-Diabody. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1398-1405.	2.8	40
80	Detection Threshold and Reproducibility of ⁶⁸ Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	2.8	21
81	A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. <i>Journal of Urology</i> , 2018, 200, 564-572.	0.2	28
82	Wrong to be Right. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1-5.	0.6	3
83	Anatomic and Molecular Imaging in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030619.	2.9	2
84	Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 177-182.	2.8	49
85	Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. <i>Journal of Urology</i> , 2018, 199, 453-458.	0.2	47
86	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1380764.	2.1	111
87	Impact of ⁶⁸ Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	2.8	113
88	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	2.8	372
89	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	1.1	58
90	First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. <i>European Urology Oncology</i> , 2018, 1, 378-385.	2.6	4

#	ARTICLE	IF	CITATIONS
91	Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. <i>Theranostics</i> , 2018, 8, 5903-5914.	4.6	33
92	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.4	10
93	Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 401.e19-401.e25.	0.8	4
94	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
95	Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. <i>Radiology</i> , 2017, 284, 109-119.	3.6	29
96	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2017, 107, 171-177.	0.5	3
97	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
98	Clinical Outcomes for Patients with Gleason Score 9â€“10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	0.9	83
99	Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. <i>Journal of Urology</i> , 2017, 197, 320-326.	0.2	173
100	Is Targeted Biopsy Applicable to Patients on Active Surveillance?. <i>European Urology</i> , 2017, 71, 181-182.	0.9	0
101	Multi-parametric magnetic resonance imaging as a management decision tool. <i>Translational Andrology and Urology</i> , 2017, 6, 472-482.	0.6	16
102	Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 1237-1242.	0.5	1
103	Prostate cancer detection with magnetic resonanceâ€“ultrasound fusion biopsy: The role of systematic and targeted biopsies. <i>Cancer</i> , 2016, 122, 884-892.	2.0	346
104	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6457-E6466.	3.3	44
105	Risk stratification of prostate cancer 2016. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S54-S59.	0.6	6
106	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	2.8	116
107	Fluorescent Imageâ€“Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. <i>Clinical Cancer Research</i> , 2016, 22, 1403-1412.	3.2	40
108	Risk stratification of prostate cancer in the modern era. <i>Current Opinion in Urology</i> , 2015, 25, 246-251.	0.9	11

#	ARTICLE	IF	CITATIONS
109	Accelerated echo planar J-resolved spectroscopic imaging in prostate cancer: a pilot validation of non-linear reconstruction using total variation and maximum entropy. <i>NMR in Biomedicine</i> , 2015, 28, 1366-1373.	1.6	13
110	A fully human scFv phage display library for rapid antibody fragment reformatting. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 307-316.	1.0	22
111	Prostate diffusion imaging with distortion correction. <i>Magnetic Resonance Imaging</i> , 2015, 33, 1178-1181.	1.0	29
112	Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. <i>American Journal of Roentgenology</i> , 2015, 205, W87-W92.	1.0	98
113	MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. <i>Frontiers in Oncology</i> , 2015, 5, 30.	1.3	20
114	Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. <i>European Urology</i> , 2015, 67, 569-576.	0.9	362
115	Applications of ImmunoPET: Using ¹²⁴ I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6367-6378.	3.2	29
116	The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer. <i>Urology</i> , 2014, 83, 369-375.	0.5	60
117	Multidimensional MR spectroscopic imaging of prostate cancer <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2014, 27, 53-66.	1.6	28
118	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 952-957.	0.8	33
119	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. <i>Cancer Research</i> , 2014, 74, 4638-4652.	0.4	179
120	Quantitative ImmunoPET of Prostate Cancer Xenografts with ⁸⁹ Zr- and ¹²⁴ I-Labeled Anti-PSCA A11 Minibody. <i>Journal of Nuclear Medicine</i> , 2014, 55, 452-459.	2.8	51
121	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. <i>Journal of Urology</i> , 2014, 192, 1367-1373.	0.2	121
122	Value of Targeted Prostate Biopsy Using Magnetic Resonance-Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. <i>European Urology</i> , 2014, 65, 809-815.	0.9	337
123	Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. <i>Prostate</i> , 2013, 73, 1378-1390.	1.2	31
124	Fine-tuning robot-assisted radical prostatectomy planning with MRI. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 766-775.	0.8	11
125	Use of MR Imaging to Determine Preservation of the Neurovascular Bundles at Robotic-assisted Laparoscopic Prostatectomy. <i>Radiology</i> , 2012, 262, 874-883.	3.6	124
126	Diffusion Tensor Magnetic Resonance Tractography of the Prostate: Feasibility for Mapping Periprostatic Fibers. <i>Urology</i> , 2012, 80, 219-223.	0.5	34

#	ARTICLE	IF	CITATIONS
127	MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 697-703.	1.9	50
128	Radical prostatectomy: value of prostate MRI in surgical planning. <i>Abdominal Imaging</i> , 2012, 37, 664-674.	2.0	36
129	Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 4-11.	0.8	24
130	Purification and direct transformation of epithelial progenitor cells from primary human prostate. <i>Nature Protocols</i> , 2011, 6, 656-667.	5.5	86
131	An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1529-1538.	3.3	55
132	Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. <i>Prostate</i> , 2010, 70, 491-501.	1.2	130
133	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. <i>Nature Medicine</i> , 2010, 16, 1414-1420.	15.2	280
134	The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 473-479.	0.8	100
135	LEF1 in Androgen-Independent Prostate Cancer: Regulation of Androgen Receptor Expression, Prostate Cancer Growth, and Invasion. <i>Cancer Research</i> , 2009, 69, 3332-3338.	0.4	89
136	The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 268-276.	0.8	76
137	Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. <i>Prostate</i> , 2008, 68, 139-151.	1.2	34
138	Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7488-7496.	3.2	63
139	Androgen Receptor and Invasion in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 1128-1135.	0.4	102
140	Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. <i>Protein Engineering, Design and Selection</i> , 2008, 22, 209-216.	1.0	38
141	What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy?. <i>Nature Reviews Urology</i> , 2007, 4, 650-651.	1.4	0
142	A Novel Dual-targeted Lentiviral Vector Leads to Specific Transduction of Prostate Cancer Bone Metastases In Vivo After Systemic Administration. <i>Molecular Therapy</i> , 2007, 15, 1973-1981.	3.7	54
143	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. <i>Cancer</i> , 2007, 109, 2239-2247.	2.0	236
144	Improvements in prostate brachytherapy dosimetry due to seed stranding. <i>Brachytherapy</i> , 2007, 6, 44-48.	0.2	21

#	ARTICLE	IF	CITATIONS
145	Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. <i>Biochemical Pharmacology</i> , 2006, 72, 1257-1267.	2.0	12
146	What are the operating characteristics of PSA screening for prostate cancer?. <i>Nature Reviews Urology</i> , 2006, 3, 74-75.	1.4	0
147	Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. <i>Pancreas</i> , 2005, 31, 119-125.	0.5	81
148	Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2237-2243.	3.2	49
149	Anti-“Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism. <i>Cancer Research</i> , 2005, 65, 9495-9500.	0.4	82
150	Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases. <i>Clinical Cancer Research</i> , 2005, 11, 2591-2596.	3.2	195
151	Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8351-8356.	3.2	60
152	Genetic alterations in prostate cancer. <i>Current Prostate Reports</i> , 2004, 2, 51-59.	0.1	0
153	Genetic alterations in prostate cancer. <i>Current Urology Reports</i> , 2004, 5, 157-165.	1.0	5
154	Trefoil factor 3 is overexpressed in human prostate cancer. <i>Prostate</i> , 2004, 61, 209-214.	1.2	53
155	Prostate Stem Cell Antigen Expression is Associated With Gleason Score, Seminal Vesicle Invasion and Capsular Invasion in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 1117-1121.	0.2	110
156	Molecular Markers and Prostate Cancer Prognosis. <i>Clinical Prostate Cancer</i> , 2004, 3, 157-164.	2.1	20
157	860: Prostate Stem Cell Antigen (PSCA) Expression is Associated with Gleason Score, Seminal Vesicle Invasion, and Capsular Invasion in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 227-228.	0.2	0
158	Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. <i>Prostate</i> , 2003, 55, 9-19.	1.2	23
159	Preoperative p27 Status is an Independent Predictor of Prostate Specific Antigen Failure Following Radical Prostatectomy. <i>Journal of Urology</i> , 2003, 169, 1325-1330.	0.2	51
160	Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. <i>Urology</i> , 2003, 61, 1187-1192.	0.5	17
161	Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 401-406.	3.3	56
162	Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene. <i>Molecular Endocrinology</i> , 2002, 16, 2323-2337.	3.7	54

#	ARTICLE	IF	CITATIONS
163	Role of prostate stem cell antigen in prostate cancer research. <i>Current Opinion in Urology</i> , 2002, 12, 401-406.	0.9	23
164	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. <i>Journal of Urology</i> , 2002, 168, 2615-2623.	0.2	11
165	Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. <i>Molecular Cancer Research</i> , 2002, 1, 113-21.	1.5	107
166	Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. , 2000, 27, 95-103.		97
167	Target antigens for prostate cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 437-449.	2.7	28
168	Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. , 1999, 40, 269-273.		45
169	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. <i>Journal of Urology</i> , 1999, 162, 659-664.	0.2	233
170	Stem cell genes in androgen-independent prostate cancer. , 1998, 17, 391-399.		50
171	LOW P27 EXPRESSION PREDICTS POOR DISEASE-FREE SURVIVAL IN PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 1998, 159, 941-945.	0.2	278
172	Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. <i>Nature Medicine</i> , 1997, 3, 402-408.	15.2	356